GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis

NCT01451905•University Hospital, Gentofte, Copenhagen

Summary

To examine GLP-1 receptors in skin of psoriasis patients compared with the skin of humans with no skin disease

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

•Caucasians above 18 years of age
•Plaque psoriasis
•PASI score \>10
•No treatment or stable treatment of psoriasis during at least 3 months before inclusion
•Steady weight through 3 months with a body mass index (BMI) above 27 kg/m2
•Normal blood pressure

•Psoriasis arthritis
•Fasting plasma glucose \> 7.5 mmol/L or HbA1c \> 7.5%
•Type 1 diabetes
•Treatment for type 2 diabetes with GLP-1-based medicine (DDP-4-inhibitors or GLP-1-receptor-agonists)
•Heart failure, NYHA class III-IV
•Uraemia, end-stage renal disease, or any other cause of impaired renal function with s-creatinine \>150 µM and/or albuminuria
•Liver disease (alanine amino transferase (ALAT) and/or aspartate amino transferase (ASAT) \>2 x upper normal serum levels)
•Anaemia
•Acute or chronic pancreatitis
•Struma or thyroid cancer
+2 more criteria

Locations (1)

Gentofte Hospital

Hellerup, Denmark

Key Dates

Start Date

August 1, 2011

Primary Completion Date

December 1, 2012

Completion Date

December 1, 2012

Last Updated

June 21, 2012

Enrollment

ESTIMATED participants

Conditions

Reduction of Psoriasis Following Liraglutide Therapy in Terms of PASI and DLQI

Interventions

Liraglutide

DRUG

Placebo

DRUG

Contacts

Annesofie Faurschou, MD PhD

CONTACT